

European All-comers' Multicentric Prospective REGISTRY on LUMINOR® Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.

NCT04743180

Status RECRUITING
Sponsor iVascular S.L.U.
Enrollment 500 participants

Key Eligibility Criteria

Inclusion (11)

- e 18years of age
- Rutherford Clinical Category 2-5
- The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study, voluntarily agrees to participation, is willing to provide 5-year informed consent and has duly signed the informed consent form (ICF)
- Significant (e 70%) stenosis or occlusion of a native femoropopliteal artery
- TASC II Class A to D Lesions
- ... and 6 more (see full listing online)

Exclusion (6)

- Women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children
- Patient is contraindicated to use Luminor Drug Eluting Balloon per the current Instructions For Use (IFU)
- Life expectancy of < 1year
- Patient is currently participating in an investigational drug or other device study or previously enrolled in this study
- Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication
- ... and 1 more (see full listing online)

Locations (15 total)

Centre Hospitalier Universitaire Pellegrin, Bordeaux, Nouvelle-Aquitaine, France
Clinique Générale Annecy, Annecy, France
Clinique Rhône Durance, Avignon, France
... and 12 more locations

<https://clinicaltrials.gov/study/NCT04743180>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).